Pharmacy Compounding Accreditation Board seeks new executive director
WASHINGTON — The Pharmacy Compounding Accreditation Board is looking for a new executive director following the departure of Joe Cabaleiro, the group said Wednesday.
The formal search will start in January, and the new executive director will oversee accreditation programs for compounding pharmacies and lead compounding initiatives to enhance patient care and improve quality practices. Interested parties may contact National Community Pharmacists Association chief of staff Beverly Martin.
"Pharmacist compounding services, the art of customizing medications for a patient’s unique healthcare needs based on a prescriber’s order, continues to be in high demand," PCAB president Douglas Hoey said; Hoey is also CEO of the NCPA. "To meet the high standards set forth for PCAB accreditation, an accredited compounding pharmacy has proven that it is providing a valuable healthcare service to its community."
FDA approves new topical scar treatment
PETALUMA, Calif. — The Food and Drug Administration has approved a new topical drug for treating scars made by Oculus Innovative Sciences, the drug maker said Wednesday.
The FDA has approved Microcyn scar-management hydrogel, used to treat scars resulting from burns, surgery and trauma wounds. Oculus and a partnering company, Quinnova Pharmaceuticals, intend to start selling the drug in the first half of next year.
"We have known for years that there has been a practitioner demand for an efficacious and safe prescription treatment to manage hypertrophic and keloid scarring," Quinnova CEO Jeffrey Day said. "Having seen firsthand the compelling impact that our Microcyn-based technology products have had on the management of conditions such as atopic dermatitis, we are equally excited about its potential as well in managing scars."
Generics to drive down HIV drug sales in next decade
BURLINGTON, Mass. — The availability of new generic drugs for treating HIV will erode sales of HIV antiretroviral drugs into the next decade in developed countries, according to a new report.
Healthcare market research firm Decision Resources released the report Wednesday, showing that sales of antiretroviral drugs in the United States, France, Germany, the United Kingdom, Spain, Italy and Japan would be $13.1 billion in 2022, down from 2012’s $13.4 billion.
Meanwhile, such single-tablet regimens as Atripla (efavirenz; emtricitabine; tenofovir) from Gilead Sciences and Bristol-Myers Squibb will drive sales in the future.